Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.08
-0.075-1.22%
Last update: Dec 16, 1:20 PM
Comments
Loading...
Eupraxia Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:EPRX | Benzinga
Eupraxia Pharmaceuticals Inc has a consensus price target of $10.67 based on the ratings of 3 analysts. The high is $12 issued by HC Wainwright & Co. on August 20, 2025. The low is $9 issued by Rodman & Renshaw on November 14, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on August 20, 2025, July 24, 2025, and June 26, 2025, respectively. With an average price target of $11.67 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 91.73% upside for Eupraxia Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Rodman & Renshaw
1calculated from analyst ratings
Analyst Ratings for Eupraxia Pharmaceuticals
FAQ
What is the target price for Eupraxia Pharmaceuticals (EPRX) stock?
The latest price target for Eupraxia Pharmaceuticals (NASDAQ:EPRX) was reported by HC Wainwright & Co. on August 20, 2025. The analyst firm set a price target for $12.00 expecting EPRX to rise to within 12 months (a possible 97.21% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Eupraxia Pharmaceuticals (EPRX)?
The latest analyst rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX) was provided by HC Wainwright & Co., and Eupraxia Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Eupraxia Pharmaceuticals (EPRX)?
There is no last upgrade for Eupraxia Pharmaceuticals
When was the last downgrade for Eupraxia Pharmaceuticals (EPRX)?
There is no last downgrade for Eupraxia Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Eupraxia Pharmaceuticals (EPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eupraxia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eupraxia Pharmaceuticals was filed on August 20, 2025 so you should expect the next rating to be made available sometime around August 20, 2026.
Is the Analyst Rating Eupraxia Pharmaceuticals (EPRX) correct?
While ratings are subjective and will change, the latest Eupraxia Pharmaceuticals (EPRX) rating was a reiterated with a price target of $12.00 to $12.00. The current price Eupraxia Pharmaceuticals (EPRX) is trading at is $6.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
